In vitro and in vivo models for assessing drug efflux transporter activity

Advanced Drug Delivery Reviews

Volumn 55, Issue 1, 2003, Pages 31-51

  Zhang, Yan ^a   Bachmeier, Corbin ^a   Miller, Donald W ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Drug efflux transporter activity; In vitro model; In vivo model

Indexed keywords

PROTEINS; SUBSTRATES;

DRUG EFFUX TRANSPORTER ACTIVITY;

DRUG INFUSION;

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATASE; AMPRENAVIR; BREAST CANCER RESISTANCE PROTEIN; DIGOXIN; ELACRIDAR; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MUTANT PROTEIN; UNCLASSIFIED DRUG; VALSPODAR;

BIOLOGICAL MODEL; BLOOD BRAIN BARRIER; BLOOD PLACENTA BARRIER; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG TRANSPORT; ENZYME ASSAY; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; KNOCKOUT MOUSE; MEMBRANE PERMEABILITY; MOUSE MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; TRANSGENIC MOUSE; TRANSPORT KINETICS; WILD TYPE;

EID: 0037457790     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00170-9     Document Type: Article

References (108)

1. Scala S., Akhmed N., Rao U.S., Paul K., Lan L.-B., Dickstein B., Lee J.-S., Elgemeie G.H., Stein W.D., Bates S.E. P-glycoprotein substrates and antagonists cluster into two distinct groups. Mol. Pharmacol. 51:1997;1024-1033.
2. Alvarez M., Robey R., Sandor V., Nishiyama K., Matsumoto Y., Paull K., Bates S., Fojo T. Using the national cancer institute anticancer drug screen to assess the effect of MRP expression on drug sensitivity profiles. Mol. Pharmacol. 54:1998;802-814.
3. Miller D.W., Fontaine M., Kolar C., Lawson T. The expression of multidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines. Cancer Lett. 107:1996;301-306.
4. Leier I., Jedlitschky G., Buchholz U., Keppler D. Characterization of the ATP-dependent leukotriene C4 export carrier in mastocytoma cells. Eur. J. Biochem. 220:1994;599-606.
5. Sugiyama Y., Kusuhara H., Suzuki H. Kinetic and biochemical analysis of carrier-mediated efflux of drugs through the blood-brain and blood-cerebrospinal fluid barriers: importance in the drug delivery to the brain. J. Control. Release. 62:1999;179-186.
6. Lee J.-S., Paull K., Alvarez M., Hose C., Monks A., Grever M., Fojo A.T., Bates S.E. Rhodamine efflux patterns predict P-glycoprotein substrates in the national cancer institute drug screen. Mol. Pharmacol. 46:1994;627-638.
7. Polli J., Wring S., Humphreys J., Huang L., Morgan J., Webster L., Serabjit-Singh C. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther. 299:2001;620-628.
8. Eneroth A., Astrom E., Hoogstraate J., Schrenk D., Conrad S., Kauffmann H., Gjellan K. Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction. Eur. J. Pharm. Sci. 12:2001;205-214.
9. Wijnholds J., Mol C., van Deemter L., de Haas M., Scheffer G., Baas F., Beijnen J., Scheper R., Hatse S., Clercq E., Balzarini J., Borst P. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc. Natl. Acad. Sci. USA. 97:2000;7476-7481.
10. Ilias A., Urban Z., Seidl T., Saux O.L., Sinko E., Boyd C., Sarkadi B., Varadi A. Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6). J. Biol. Chem. 277:2002;16860-16867.
11. Yamazaki M., Neway W.E., Ohe T., Chen I.-W., Rowe J.F., Hochman J.H., Chiba M., Lin J.H. In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results. J. Pharmacol. Exp. Ther. 296:2001;723-735.
12. Evers R., Zaman G.J., van Deemter L., Jansen H., Calafat J., Oomen L.C., oude Elferink R.P., Borst P., Schinkel A.H. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J. Clin. Invest. 97:1996;1211-1218.
13. Adachi Y., Suzuki H., Sugiyama Y. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm. Res. 18:2001;1660-1668.
14. Gaillard P.J., van der Sandt I.C.J., Voorwinden L.H., Vu D., Nielsen J.L., de Boer A.G., Breimer D.D. Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier. Pharm. Res. 17:2000;1198-1205.
15. Batrakova E.V., Li S., Miller D.W., Kabanov A.V. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm. Res. 16:1999;1366-1372.
16. Prueksaritanont T., Deluna P., Gorham L.M., Ma B., Cohn D., Pang J., Xu X., Leung K., Lin J.H. In vitro and in vivo evaluation of intestinal barriers for the zwitterion L-767,679 and its carboxyl ester prodrug L-775,318. Drug Metab. Dispos. 26:1998;520-527.
17. Schuetz E.G., Yasuda K., Arimori K., Schuetz J.D. Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid benzo(a)pyrene. Arch. Biochem. Biophys. 350:1998;340-347.
18. Evers R., Kool M., van Deemter L., Janssen H., Calafat J., Oomen L.C.J.M., Paulusma C.C., oude Elferink R.P.J., Baas F., Schinkel A.H., Borst P. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Invest. 101:1998;1310-1319.
19. Paulusma C.C., van Geer M.A., Evers R., Heijn M., Ottenhoff R., Borst P., oude Elferink R.P. Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione. Biochem. J. 338:1999;393-401.
20. Kool M., van der Linden M., de Haas M., Scheffer G.L., de Vree J.M.L., Smith A.J., Jansen G., Peters G.J., Ponne N., Scheper R.J., oude Elferink R.P.J., Baas F., Borst P. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. USA. 96:1999;6914-6919.
21. Rosenberg M., Velarde G., Ford R., Martin C., Berridge G., Kerr I., Callaghan R., Schmidlin A., Wooding C., Linton K., Higgins C. Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle. EMBO J. 20:2001;5615-5625.
22. Chang X., Hou Y., Riordan J. Stimulation of ATPase activity of purified multidrug resistance-associated protein by nucleoside diphosphates. J. Biol. Chem. 273:1998;23844-23848.
23. Hooijberg J., Broxterman H., Heijn M., Fles D., Lankelma J., Pinedo H. Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein. FEBS Lett. 413:1997;344-348.
24. Robey R., Honjo Y., van de Laar A., Miyake K., Regis J., Litman T., Bates S. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim. Biophys. Acta. 1512:2001;171-182.
25. Boulton D., DeVane C., Liston H., Markowitz J. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 71:2002;163-169.
26. Garrigues A., Nugier J., Orlowski S., Ezan E. A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein. Anal. Biochem. 305:2002;106-114.
27. Batrakova E.V., Li S., Vinogradov S.V., Alakhov V.Y., Miller D.W., Kabanov A.V. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J. Pharmacol. Exp. Ther. 299:2001;483-493.
28. Sharom F.J., Yu X., Lu P., Liu R., Chu J.W.K., Szabo K., Muller M., Hose C.D., Monks A., Varadi A., Seprodi J., Sarkadi B. Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted system and intact cells. Biochem. Pharmacol. 58:1999;571-586.
29. Chang X., Hou Y., Riordan J. ATPase activity of purified multidrug resistance-associated protein. J. Biol. Chem. 272:1997;30962-30968.
30. Annaert P., Turncliff R., Booth C., Thakker D., Brouwer K. P-glycoprotein-mediated in vitro biliary excretion in sandwich-cultured rat hepatocytes. Drug Metab. Disp. 29:2001;1277-1283.
31. Pallis M., Turzanski J., Langabeer S., Russell N. Reproducible flow cytometric methodology for measuring multidrug resistance in leukaemic blasts. Adv. Exp. Med. Biol. 457:1999;77-88.
32. Sharom F.J., Yu X., Chu J.W.K., Doige C.A. Characterization of the ATPase activity of P-glycoprotein from multidrug resistant Chinese hamster ovary cells. Biochem. J. 308:1995;381-390.
33. Rao U. Mutation of glycine 185 to valine alters the ATPase function of the human P-glycoprotein expressed in Sf9 cells. J. Biol. Chem. 270:1995;6686-6690.
34. Ambudkar S.V., Lelong I.H., Zhang J.P., Cardarelli C.O., Gottesman M.M., Pastan I. Partial purification and reconstitution of the human multidrug-resistance pump - characterization of the drug-stimulatable ATP hydrolysis. Proc. Natl. Acad. Sci. USA. 89:1992;8472-8476.
35. Borgnia M., Eytan G., Assaraf Y. Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J. Biol. Chem. 271:1996;3163-3171.
36. Urbatsch I.L., Senior A.E. Effects of lipids on ATPase activity of purified Chinese hamster P-glycoprotein. Arch. Biochem. Biophys. 316:1995;135-140.
37. Sharom F.J., DiDiodato G., Yu X., Ashbourne K.J.D. Interaction of the P-glycoprotein multidrug transporter with peptides and ionophores. J. Biol. Chem. 270:1995;10334-10341.
38. Scarborough G.A. Drug-stimulated ATPase activity of the human P-glycoprotein. J. Bioenerg. Biomemb. 27:1995;37-41.
39. Borst P., Schinkel A.H. Genetic dissection of the function of mammalian P-glycoproteins. Trends Genet. 13:1997;217-222.
40. Schinkel A.H., Smit J.J.M., van Tellington O., Beijnen J.H., Wagenaar E., van Deemter L., Mol C.A.A.M., van der Valk M., Robanus-Maandag E.C., te Riele H., Berns A.J.M., Borst P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 77:1994;491-502.
41. Dagenais C., Ducharme J., Pollack G.M. Interaction of nonpeptidic delta agonists with P-glycoprotein by in situ mouse brain perfusion: liquid chromatography-mass spectrometry analysis and internal standard strategy. J. Pharm. Sci. 91:2002;244-252.
42. Kawahara M., Sakata A., Miyashita T., Tamai I., Tsuji A. Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. J. Pharm. Sci. 88:1999;1281-1287.
43. Zong J., Pollack G.M. Morphine antinociception is enhanced in mdr1a gene-deficient mice. Pharm. Res. 17:2000;749-753.
44. Saito T., Zhang Z.J., Ohtsubo T., Noda I., Shibamori Y., Yamamoto T., Saito H. Homozygous disruption of the mdr1a P-glycoprotein gene affects blood-nerve barrier function in mice administered with neurotoxic drugs. Acta Otolaryngol. 121:2001;735-742.
45. de Lange E., Marchand S., van de Berg D., van der Sandt I., de Boer A., Delon A., Bouquet S., Couet W. In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin. Eur. J. Pharm. Sci. 12:2000;85-93.
46. Uhr M., Steckler T., Yassouridis A., Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology. 22:2000;380-387.
47. Polli J.W., Jarrett J.L., Studenberg S.D., Humphreys J., Dennis S., Brouwer K., Woolley J. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), and HIV protease inhibitor. Pharm. Res. 16:1999;1206-1212.
48. Cox D.S., Scott K.R., Gao H., Raje S., Eddington N.D. Influence of multidrug resistance (MDR) proteins at the blood-brain barrier on the transport and brain distribution of enaminone anticonvulsants. J. Pharm. Sci. 90:2001;1540-1552.
49. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J.J., Roden D.M., Wilkinson G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:1998;289-294.
50. Washington C.B., Wiltshire H.R., Man M., Moy T., Harris S.R., Worth E., Weigl P., Liang Z., Hall D., Marriott L., Blaschke T.F. The disposition of saquinavir in normal and P-glycoprotein deficient mice. Drug Metab. Disp. 28:2000;1058-1062.
51. Sparreboom A., van Asperen J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K., Borst P., Nooijen W.J., Beijnen J.H., van Tellington O. Limited oral bioavailability and active epithelial excretion of paclitaxel (taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA. 94:1997;2031-2035.
52. Beaumont K., Harper A., Smith D.A., Bennett J. The role of P-glycoprotein in determining the oral absorption and clearance of the NK2 antagonist, UK-224,671. Eur. J. Pharm. Sci. 12:2000;41-50.
53. Naruhashi K., Tamai I., Inoue N., Muraoka H., Sai Y., Suzuki N., Tsuji A. Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein. J. Pharm. Pharmacol. 53:2001;699-709.
54. Yamaguchi H., Yano I., Saito H., Inui K. Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. J. Pharmacol. Exp. Ther. 300:2002;1063-1069.
55. Mayer U., Wagenaar E., Beijnen J.H., Smit J.W., Meijer D.K., van Asperan J., Borst P., Schinkel A.H. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a P-glycoprotein. Br. J. Pharmacol. 119:1996;1038-1044.
56. Mayer U., Wagenaar E., Dorobek B., Beijnen J.H., Borst P., Schinkel A.H. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J. Clin. Invest. 100:1997;2430-2436.
57. Desrayaud S., de Lange E., Lemaire M., Bruilisauer A., de Boer A., Breimer D.D. Effect of the mdr1a P-glycoprotein gene disruption on the tissue distribution of SDZ PSC833, a multidrug resistance-reversing agent, in mice. J. Pharmacol. Exp. Ther. 285:1998;438-443.
58. van Asperen J., van Tellington O., Beijnen J.H. The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab. Disp. 28:2000;264-267.
59. Smit J.W., Schinkel A.H., Muller M., Weert B., Meijer D.K.F. Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with and mdr1a gene disruption. Hepatology. 27:1998;1056-1063.
60. Iyer L., Ramirez J., Shepard D.R., Bingham C.M., Hossfeld D.K., Ratain M.J., Mayer U. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother. Pharmacol. 49:2002;336-341.
61. Luker G.D., Dahlheimer J.L., Ostlund R.E., Piwnica-Worms D. Decreased hepatic accumulation and enhanced esterification of cholesterol in mice deficient in mdr1a and mdr1b P-glycoproteins. J. Lipid Res. 42:2001;1389-1394.
62. Thompson S.J., Koszdin K., Bernards C.M. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology. 92:2000;1392-1399.
63. King M., Su W., Chang A., Zuckerman A., Pasternak G.W. Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs. Nat. Neurosci. 4:2001;268-274.
64. Liu J., Chen H., Miller D., Saavedra J., Keefer L., Hohnson D., Klaassen C., Waalkes M. Overexpression of glutathione S-transferase pi and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. Mol. Pharmacol. 60:2001;302-309.
65. Vernhet L., Allian N., Bardiau C., Anger J., Fardel O. Differential sensitivities of MRP1-overexpressing lung tumor cells to cytotoxic metals. Toxicology. 142:2000;127-134.
66. Kala S., Neely M., Kala G., Prater C., Atwood D., Rice J., Lieberman M. The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J. Biol. Chem. 275:2000;33404-33408.
67. Liu J., Liu Y., Powell D.A., Waalkes M.P., Klaassen C.D. Multidrug-resistance mdr1a/1b double knockout mice are more sensitive than wild type mice to acute arsenic toxicity, with higher arsenic accumulation in tissues. Toxicology. 170:2002;55-62.
68. Hayday A., Theodoridis E., Ramsburg E., Shires J. Intraepithelial lymphosites: exploring the third way in immunology. Nat. Immunol. 2:2001;997-1003.
69. Eisenbraun M.D., Mosley R.L., Teitelbaum D.H., Miller R.A. Altered development of intestinal intraepithelial lymphocytes in P-glycoprotein-deficient mice. Dev. Comp. Immunol. 24:2000;783-795.
70. Borst P., Evers R., Kool M., Wijnholds J. The multidrug resistance protein family. Biochim. Biophys. Acta. 1461:1999;347-357.
71. Cui Y., Konig J., Bucholz J.K., Spring H., Leier I., Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. 55:1999;929-937.
72. Hooijberg J.H., Broxterman H.J., Kool M., Assaraf Y., Peters G., Noordhuis P., Scheper R., Borst P., Pinedo H., Jansen G. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 59:1999;2532-2535.
73. Kusuhara H., Suzuki H., Naito M., Tsuruo T., Sugiyama Y. Characterization of efflux transport of organic anions in a mouse brain capillary endothelial cell line. J. Pharmacol. Exp. Ther. 285:1998;1260-1265.
74. Konig J., Rost D., Cui Y., Keppler D. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology. 29:1999;1156-1163.
75. Muller M., Roelofsen H., Jansen P.L. Secretion of organic anions by hepatocytes: involvement of homologues of the multidrug resistance protein. Semin. Liver Dis. 16:1996;211-220.
76. Makhey V.D., Guo A., Norris D.A., Hu P., Yan J., Sinko P. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in caco-2 cells. Pharm. Res. 15:1998;1160-1167.
77. Peng K.C., Cluzeaud F., Bens M., van Huyen J., Wioland M., Lacave R., Vandewalle A. Tissue and cell distribution of the multidrug resistance-associated protein (MRP) in mouse intestine and kidney. J. Histochem. Cytochem. 47:1999;757-768.
78. Kool M., de Haas M., Scheffer G.L., Scheper R., van Eijk M., Juijn J., Baas F., Borst P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5 homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 57:1997;3537-3547.
79. Bera T.K., Lee S., Salvatore G., Lee B., Pastan I. MRP8, a new member of ABC transporter superfamily. Identified by EST database mining and gene prediction program, is highly expressed in breast cancer. Mol. Med. 7:2001;509-516.
80. Bera T.K., Iavarone C., Kumar V., Lee S., Lee B., Pastan I. MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer. Proc. Natl. Acad. Sci. USA. 99:2002;6997-7002.
81. Leslie E.M., Deeley R.G., Cole S.P. Toxicological relevance of the multidrug resistance protein1, MRP1 (ABCC1) and related transporters. Toxicology. 167:2001;3-23.
82. Wijnholds J., Scheffer G.L., van der Valk M., van der Valk P., Beijnen J.H., Scheper R.J., Borst P. Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage. J. Exp. Med. 188:1998;797-808.
83. Lorico A., Rappa G., Finch R.A., Yang D., Flavell R.A., Sartorelli A.C. Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. Cancer Res. 57:1997;5238-5242.
84. Wijnholds J., Evers R., van Leusden M., Mol C.A., Zaman G.J., Mayer U., Beijnen J.H., van der Valk M., Krimpenfort P., Borst P. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat. Med. 3:1997;1275-1279.
85. Sun H., Johnson D.R., Finch R.A., Sartorelli A.C., Miller D.W., Elmquist W.F. Transport of fluorescein in MDCKII-MRP transfected cells and mrp1-knockout mice. Biochem. Biophys. Res. Commun. 284:2001;863-869.
86. Regina A., Koman A., Piciotti M., Hafney B.E., Center M., Bergmann R., Couraud P., Roux F. Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J. Neurochem. 71:1998;705-715.
87. Massey T., Smith G., Tam A. Mechanisms of aflatoxin B1 lung tumorigenesis. Exp. Lung Res. 26:2000;673-683.
88. Sengstag C. The molecular mechanism of aflatoxin B1-induced liver cancer: is mitotic recombination involved? Mol. Carcinog. 19:1997;147-152.
89. Loe D., Stewart R., Massey T., Deeley R., Cole S. ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. Mol. Pharmacol. 51:1997;1034-1041.
90. Lorico A., Nesland J., Emilsen E., Fodstad O., Rappa G. Role of the multidrug resistance protein 1 gene in the carcinogenicity of aflatoxin B1: investigations using mrp1-null mice. Toxicology. 171:2002;201-205.
91. Lorico A., Bertola A., Baum C., Fodstad O., Rappa G. Role of the multidrug resistance protein 1 in protection from heavy metal oxyanions: investigations in vitro and in MRP1-deficient mice. Biochem. Biophys. Res. Commun. 291:2002;617-622.
92. Umbenhauer D.R., Lankas G.R., Pippert T.R., Wise L., Cartwright M., Hall S., Beare C. Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol. Appl. Pharmacol. 146:1997;88-94.
93. Pippert T.R., Umbenhauer D.R. The subpopulation of CF-1 mice deficient in P-glycoprotein contains a murine retroviral insertion in the mdr1a gene. J. Biochem. Mol. Toxicol. 15:2001;83-89.
94. Kwei G.Y., Alvaro R.F., Chen Q., Jenkins H., Hop C., Keohane C., Ly V., Strauss J., Wang R., Wang Z., Pippert T., Umbenhauer D. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab. Dispos. 27:1999;581-587.
95. Cisternino S., Rousselle C., Dagenais C., Scherrmann J. Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice. Pharm. Res. 18:2001;183-190.
96. Lankas G.R., Wise L.D., Cartwright M.E., Pippert T., Umbenhauer D. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod. Toxicol. 12:1998;457-463.
97. Jansen P.L., Peters W.H., Lamers W.H. Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. Hepatology. 5:1985;573-579.
98. Xiong H., Turner K.C., Ward E.S., Jansen P., Brouwer K. Altered hepatobiliary disposition of acetominophen glucuronide in isolated perfused livers from multidrug resistance-associated protein 2-deficient TR(-) rats. J. Pharmacol. Exp. Ther. 295:2000;512-518.
99. Salamon A., Vielnascher E., Hagenauer B., Szekeres T., Szekeres-Fritzer M., Thalhammer T., Jager W. Metabolism of the new ribonucleotide reductase inhibitor amidox in the isolated perfused rat liver. Anticancer Res. 20:2000;3521-3526.
100. Salamon A., Hagenauer B., Thalhammer T., Szekeres T., Krohn K., Jayaram H., Jager W. Metabolism and disposition of the novel antileukaemic drug. Benzamide riboside, in the isolated perfused rat liver. Life Sci. 69:2001;2489-2502.
101. Gaugg M., Haslmayer P., Jager W., Thalhammer T. Influence of hypotonic stress on the biliary excretion of doxorubicin in Wistar and TR(-) rats. Anticancer Res. 21:2001;2745-2751.
102. Huang L., Smit J.W., Meijer D.K., Vore M. Mrp2 is essential for estradiol-17beta(beta-D-glucuronide)-induced cholestasis in rats. Hepatology. 32:2000;66-72.
103. Kostrubsky V.E., Vore M., Kindt E., Burliegh J., Rogers K., Peter G., Altrogge D., Sinz M. The effect of troglitazone biliary excretion on metabolite distribution and cholestasis in transporter-deficient rats. Drug Metab. Dispos. 29:2001;1561-1566.
104. Dietrich C.G., de Waart D., Ottenhoff R., Bootsma A., van Gennip A., Elferink R. Mrp2-deficiency in the rat impairs biliary and intestinal excretion and influences metabolism and disposition of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo. Carcinogenesis. 22:2001;805-811.
105. Dietrich C.G., de Waart D., Ottenhoff R., Schoots I., Elferink R. Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats. Mol. Pharmacol. 59:2001;974-980.
106. Schinkel A.H., Mayer U., Wagenaar E., Mol C., van Deemter L., Smit J., van der Valk M., Voordouw A., Spits H., van Tellington O., Zijlmans J., Fibbe W., Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA. 94:1997;4028-4033.
107. Wijnholds J., de Lange E., Scheffer G.L., van de Berg D., Mol C., van der Valk M., Schinkel A., Scheper R., Breimer D., Borst P. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J. Clin. Invest. 105:2000;279-285.
108. Johnson D.R., Finch R.A., Lin Z.P., Zeiss C., Sartorelli A. The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice. Cancer Res. 61:2001;1469-1476.